The Goldman Sachs Future Health Care Equity ETF (GDOC) gained momentum after positive news from its largest holding, Eli Lilly (LLY), whose price target was raised by JPMorgan. GDOC has returned 11.8% over the past three months, recovering from earlier underperformance in 2026. The fund invests actively in innovative healthcare firms, focusing on genomics, precision medicine, and digital health, and benefits from potential tailwinds like future interest rate cuts and increased M&A activity. Another key holding, Johnson & Johnson, also contributed with nearly 30% returns year-to-date and recent FDA approval for a cardiac catheter. GDOC is well-positioned for growth in the second half of the year as healthcare innovation and economic improvements drive demand.
